CD274 and non-small cell lung carcinoma: Therefore, in the current study, we evaluated the clinical effects and adverse events (AEs) of patients with PD‐L1 (‐) advanced nonsquamous NSCLC (nNSCLC) who accepted first‐line chemotherapy plus immunotherapy versus antiangiogenic therapy.